Genetic deficiency of the purine salvage enzyme adenosine deaminase (ADA) results in varying degrees of immunodeficiency, ranging from neonatal onset Severe Combined Immunodeficiency (SCID) to an adult onset immunodeficiency disorder. Multiple different mutations have now been identified in these immunodeficient patients. Additional mutations, initially identified in healthy individuals, abolish ADA in erythrocytes but retain 10-80% of activity in non-erythroid cells ('partial deficiency mutations'). In general, severity of disease correlates inversely with the amount of residual ADA expressed by the mutant enzymes and directly with the accumulation of the toxic metabolites deoxyATP and deoxyadenosine. We report two newly identified mutations (Y97C and L106V), both carried on the same allele of an immunodeficient patient who was diagnosed prenatally and successfully transplanted with haploidentical bone marrow. Based on the ability of mutant cDNAs to express ADA in vitro, the L106V mutation resulted in activity similar to 'partial' mutations (30% of normal) while the Y97C mutation resulted in detectable but markedly reduced activity (1.5% of normal). However, the presence of both mutations on the same allele virtually abolished detectable enzyme activity. Analysis of the crystallographic structure of ADA to understand the marked deleterious effect of the Y97C mutation suggested a previously unappreciated role of salt bridges in the catalytic mechanism of ADA. The patient was also heteroallelic for a previously described deletion of the promoter and exon 1. Testing of additional patients in whom we had not identified a mutation on the second allele revealed presence of this deletion in three of four patients tested. This deletion is therefore relatively common, accounting for 10% of almost 100 chromosomes studied by this and other laboratories, but is easily missed by currently used methods of mutation detection. Lastly, the finding of two mutations on the same allele that interact to reduce residual enzyme function emphasizes hazards in evaluating potential genotype-phenotype correlations in individuals analyzed only for the presence of single specific mutations.
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INTRODUCTION
Adenosine deaminase (ADA) is an enzyme of the purine salvage pathway that catalyzes the deamination of adenosine and 2′ deoxyadenosine to inosine and 2′ deoxyinosine, respectively. Inherited deficiency of ADA results in an autosomal recessive immunodeficiency disorder of varying severity. The phenotypes include classical neonatal onset rapidly fatal Severe Combined Immunodeficiency (SCID) with absence of both cellular and humoral immunity; a delayed onset, more slowly progressive disease characterized by initial retention of some humoral immunity; a later juvenile onset disease often not diagnosed till 5-8 years of age, with progressive attrition of immune function and a recently described adult onset disorder. Additionally, children have been found by population screening who have no apparent immune deficit and who lack enzyme activity in erythrocytes but express variable residual ADA (5-80% of normal ADA) in other cell types ('partial' ADA deficiency). In general, the degree of enzyme deficiency, accumulation of the toxic metabolite deoxyATP and urinary excretion of the substrate deoxyadenosine grossly correlate with severity of disease. Consistent with this diversity, >40 mutations spanning much of the 32 kb, 12 exon ADA gene on chromosome 20q13 have been identified, including deletions, missense, nonsense and splicing mutations (1) (2) (3) (4) (5) .
We have molecularly and biochemically studied the sib of a patient who died with ADA -SCID. The sib was diagnosed prenatally as ADA deficient, the diagnosis confirmed at birth and the child successfully transplanted with haploidentical bone marrow. We newly identified two missense mutations (Y97C and L106V) on the same allele that interacted to abolish residual ADA activity. The second allele contained a previously described *To whom correspondence should be addressed. Tel: +1 212 263 6276; Fax: +1 212 263 7151; Email: hirscr01@mcrcr0.med.nyu.edu deletion of the promoter and exon 1 (6) (7) (8) , which, we now report, is a relatively frequent mutation.
RESULTS

Biochemical studies
Prenatal testing for ADA deficiency by assay of ADA in cultured amniotic cells, performed because of the death of a prior sib with ADA -SCID, revealed the presence of an affected fetus (0.07 versus normal = 7.5 ± 4.1 nmol/mg protein/min). The prenatal diagnosis was confirmed after birth by demonstration of <1% of normal ADA activity in the child's RBCs and peripheral blood mononuclear cells ( Table 1) . DeoxyATP content of erythrocytes was markedly elevated (Table 2) , similar to concentrations found in patients with SCID but not as high as those we have found in patients with neonatal onset of disease. Excretion of deoxyadenosine in urine was similarly elevated. (6, 7) . PCR amplifications using primers flanking the previously reported deletion generated a 481 bp fragment in the patient and her father and in DNA from an individual homozygous for this deletion (not shown) but not in the mother or in normal (Fig. 1) . The sequence at the recombination joint was identical to that previously reported in two patients (6,7) but differed from that reported in a third patient (8) . Additionally, we tested DNA from four other patients in whom we had been able to identify a mutation on only one of the alleles. The deletion of the promoter and exon 1 was identified in three of these additional patients (Lco, GM02436 and Fa). All of the patients carried the same, more frequent, recombination joint (not shown).
We further identified two additional missense mutations, not previously reported, by direct sequence analysis of genomic DNA amplified by PCR. These were an A to G transition at nt 290, predicting a tyrosine to cysteine substitution at codon 97 (Tyr97Cys; Y97C) and a C to G transversion at nt 316 that results in a leucine to valine substitution at codon 106 (Leu106Val; L106V), both in exon 4 of genomic DNA ( Fig. 2A) . The 316 C to G transition (L106V) predicts gain of a site for PmlI in exon 4 of genomic DNA. Restriction enzyme analysis demonstrated that both the mother and the child were heterozygous for the L106V mutation (not shown). Sequence analysis of genomic DNA from the mother further demonstrated that she was heterozygous for the Y97C as well as the L106V mutation ( Fig. 2A ). To further confirm that both mutations were on the same allele, we cloned the PCR product containing exon 4 from DNA of the child and analyzed these for sequence. Only two types of clones were found, one containing only wild type sequence and the other containing both mutations (Y97C and L106V) (Fig. 2B) .
In vitro studies of expression by the two missense mutations found on one allele of the patient
To evaluate the ability of the Y97C/L106V mutations and of each of the mutations individually to express ADA, each of the mutations alone and both mutations together were introduced into a normal ADA cDNA. The mutant cDNAs were transiently expressed by co-transfection with a β-galactosidase(β-gal) cDNA into Cos cells. Lysates were adjusted to contain known amounts of β-gal activity (both to correct for any differences in efficiency of transfection and to allow for semi-quantitative analysis), electrophoresed in starch gels and ADA activity assessed by in situ staining. Activity was compared with that expressed by a normal ADA cDNA and by different mutant cDNAs (R156H, L107P, R211C, T233I or A215T) (9, 14, 32) , using different amounts of total β-gal activity to allow for semi-quantitative analysis as illustrated in Figure 3 and summarized in Table 3 . The L106V mutation expressed considerable ADA, although substantially less than the normal ADA cDNA (30% of normal) (Fig. 3 , Table 3 ). Comparison of the L106V mutation with several previously described partial mutations, revealed that the L106V mutant expressed the greatest activity among the four mutations tested, with L106V (∼30%) > T233I (∼16-20%) > A215T (∼8%) > Arg211Cys (∼4%) ( Table  3 and data not shown). By contrast to the L106V mutant cDNA, the Y97C mutation expressed only very low amounts of ADA activity (1-1.5% of normal). Most significantly, presence of both mutations together (L106V/Y97C), virtually abolished expression of ADA activity (Fig. 3, Table 3 ). Lastly we compared the activity of the L106V mutant with a mutation (L107P) at the adjacent codon (14) . In contrast to the L106V mutant, the L107P mutant cDNA did not express detectable activity (not shown).
We additionally utilized coupled transcription/translation to compare the ability of the mutant cDNAs to direct in vitro translation of enzyme protein. All of the mutant constructs (Y97C, L106V, Y97C/L106V, R211C, T233I and A215T) gave rise to protein that did not differ in size or amount as compared with the normal ADA cDNA (Fig. 4A) , as determined by SDS electrophoresis and autoradiography. Despite the equal amounts of protein, no ADA activity could be detected following transcription/translation of Y97C, Y97C/L106V and R211C mutant ADA cDNAs, as determined by electrophoresis in starch gel and in situ staining for ADA activity (Fig. 4B) . Markedly diminished activity was expressed by the L106V, T233I and A215T mutant ADA cDNAs. These results suggest that all the mutations directly affect ADA activity independent of any effect on protein stability. Figure 3 and all methods. b ND, none detectable.
DISCUSSION
We have studied a child diagnosed prenatally as ADA deficient, confirmed by laboratory tests after birth as immunodeficient and ADA deficient, and successfully transplanted with haploidentical marrow prior to development of the clinical complications of immunodeficiency. Based on the history of her affected sib, who retained immunoglobulins and survived to 27 months of age, the phenotype would fall into the category of 'delayed', rather than 'fulminant neonatal' onset. The metabolite concentrations present in this second child (not determined in the proband) were consistent with the phenotype of the proband. Molecular studies of the child and her parents as well as of additional patients led to (i) unexpected discovery of a complex allele, (ii) demonstration of the frequent lack of diagnosis of a relatively frequent mutation by currently used PCR based diagnosis, and (iii) the suggestion of a previously unappreciated role of salt bridges in the catalytic mechanism. We identified two new missense mutations (Y97C and L106V) carried on the same allele of this child. Based on in vitro transient expression of mutant ADA cDNAs, the L106V mutation resulted in activity similar to 'partial' mutations (∼30% of normal) while the Y97C mutation resulted in detectable but markedly reduced activity (∼1-1.5% of normal), similar to R156H, a mutation previously reported to express detectable ADA (9) . However, the presence of both mutations together on the same allele (L106V/Y97C) interacted to abolish detectable enzyme activity. The deleterious effects of all the mutations studied occurred independently of protein stability, as shown by the studies of in vitro coupled transcription translation, where all resulted in translation of normal amounts of protein, yet still showed alterations in enzyme activity. Nonetheless, alterations in stability of the mutant proteins could further contribute to the in vivo Comparison of expression of ADA by mutant cDNAs containing Y97C, L106V and Y97C/L106V mutations as compared with a normal ADA cDNA and previously identified mutant R156H. Cos cells were co-transfected with a β-gal expressing construct and the indicated mutant or normal ADA cDNA. The β-gal activity was determined in the cell lysates, known amounts of β-gal activity were electrophoresed on starch gel to separate human from endogenous Cos ADA and ADA activity was detected in situ as described in Materials and Methods. The upper anodal band represents the endogenous ADA of the Cos cells (monkey kidney) while the lower band represents human ADA. The amount of β-gal activity in the normal ADA cDNA was taken as one unit in each experiment and the amounts of β-gal for each mutant indicated as fold increase. Preliminary experiments (not shown) were used to estimate the appropriate fold dilution to allow for semi-quantitative comparison. The L106V exhibits ∼30% of normal activity, the Y97C mutant cDNA in vitro expressed low activity (∼1-1.5% of normal), similar to that expressed by an R156H mutant (9) and the Y97C/L106V double mutant cDNA abolished ADA activity. deleterious effects. Differences between enzyme expression by the L106V, T233I and A215T 'partial' mutations and between the R2111C, R156H and Y97C mutations could be seen following transient transfection into SV 40 transformed cells but were not appreciated following coupled transcription/translation. In vitro transient expression of mutant ADA cDNAs in Cos cells may be more sensitive than expression following in vitro coupled transcription/translation.
The murine ADA enzyme has been crystallized and areas of evolutionary conservation from Escherichia coli to man have been identified, providing a basis for analyzing effects of mutations (11) . Since the protein sequence of the mouse ADA is 83% identical with the human sequence we can examine the functional implication of these mutations from a structural point of view by inspecting the available X-ray crystal structure of the mouse ADA (10, 12, 13) . The X-ray structure of mouse ADA 35 S-labeled translation products were generated from wild type and mutant transcripts. They were not produced in the absence of mRNA and are presumably due to aberrant translation or to proteolysis (9) . (B) In situ ADA assay of products from in vitro transcription translation. L106V, T233I and A215T mutant proteins show lower enzyme activity than normal ADA. By contrast, the enzyme activities of the R211C, Y97C and Y97C/L106V mutants were undetectable.
A B
complexed with a transitional-state analog shows that it contains a parallel α/β barrel motif with eight central β strands surrounded by eight α helices, one of the most frequent structural motifs occurring in enzymatic proteins (12) . The active site of the protein is located in a deep pocket at the C-terminal end of the β barrel with a Zn 2+ cofactor at the bottom of the pocket. This active site is covered by a long insertion between the first β-strand and the first α-helix of the barrel. It has been observed by Wilson et al. (12) that the side of the substrate towards the opening of the active site pocket only sees hydrophobic residues, and the authors described them as the lids of the active site pocket. Leu106 is one of these hydrophobic residues that surrounds the opening of the active site (Fig. 5A) , and its side chain is <3.5 Å away from the substrate in the X-ray structure of mouse ADA complexed with 1-deazaadenosine (13) . The mutation of Leu106 to a shorter Val residue presumably reduces the stability of the substrate binding hence leading to a partial reduction of the activity of the enzyme. The Leu107Pro mutation we previously reported (14) could have changed the backbone structure of this region, leading to a more drastic reduction of the activity. While Leu106 may directly interact with the substrates of ADA, Tyr97 is located ∼20 Å away from the active side at the other end of the β-barrel. It is therefore not possible for Tyr97 to have direct contact with the substrates. However, by carefully inspecting the X-ray structure of mouse ADA, we found that Tyr97 is connected to the active site by a chain of charged residues (Fig. 5B) . Three charged residues, Glu99, Arg235 and Glu260, build a salt bridge between Tyr97 and His15, one of the residues coordinating the zinc cofactor. The pairwise distances of the side chain of these residues are from 2.33 to 2.65 Å in the X-ray structure, indicating strong interactions between them. Furthermore, this salt bridge is completely buried in the center of the β-barrel (although Tyr97 has partial access to the solvent). This interesting arrangement and the fact the Y97C mutation severely reduced the activity of the enzyme make one speculate that Tyr97 and the buried salt bridge play a direct role in the reaction catalyzed by the enzyme. This hypothesis is further supported by the finding that an Arg235Trp mutation that would also disrupt this salt bridge also severely reduced the activity of the enzyme (Hirschhorn et al., unpublished) . However, the precise role of Tyr 97 and the buried salt bridge need to be investigated by further studies.
Analysis of evolutionary conservation is also consistent with the observed effects on enzyme activity. Comparison of the amino acid sequences of E.coli, murine and human adenosine deaminases reveals that tyrosine at codon 97 is completely conserved between E.coli and mammalian ADA ( Table 4 ). The substitution of Cys for Tyr is a non-conservative substitution, consistent with the major deleterious effect of this mutation on enzyme activity. By contrast, leucine at codons 106 and 107 are not evolutionarily conserved (Table 4) (11) . However, while the L106V mutation retains ∼30% activity of ADA, the L107P mutation abolishes activity. This could reflect differences in the nature of the substitutions. The Leu106 to Val substitution is a conservative substitution while introduction of proline residues into a loop would change the backbone configuration and contribute to the loss of enzyme activity. Complex alleles containing more than one mutation have been reported in several disorders, beginning with early studies of hemoglobinopathies (15) . These complex alleles may represent the combination of a normal common polymorphism with a deleterious mutation, the presence of two deleterious mutations derived by crossover with a pseudogene, or the presence of two deleterious mutations that, presumably, occurred independently. Clinical studies in cystic fibrosis have indicated a beneficial modulating effect of a second mutation on the common ∆508 mutation allele (16) . In Gaucher's disease the presence of complex alleles derived from a pseudogene is well recognized (17) . In adenosine deaminase, two common polymorphic amino acid substitutions have been identified; Lys80Arg which has no apparent effect on enzyme activity in vitro (18) and Asp8Asn, responsible for the type 2 ADA biochemical polymorphism (19) .
Several studies have documented a somewhat lower ADA activity in individuals carrying the type 2 polymorphism and, in addition, there have been multiple reports on differences in disease incidence in individuals carrying the type 2 versus the common type 1 ADA polymorphisms, (20) (21) (22) (23) (24) , although none of these proposed associations have been definitively confirmed. In addition to these amino acid substitutions, at least eight missense mutations that either abolish or markedly reduce ADA activity in erythrocytes have been identified during screening of normal populations (14, 25) . These, missense mutations, termed partial mutations because of retention of considerable ADA in nonerythroid cells, have primarily been identified in individuals of African, Caribbean and Spanish descent. By contrast, the child reported here is believed to be of Northern European Caucasian descent, a population in which partial mutations with substantial activity have not been previously reported. Therefore, although one would expect complex alleles with combinations of partial and 'severe' mutations primarily in individuals of African or Spanish derivation, the observations reported here suggest that such partial mutations as well as the ADA type 2 variant, may be present in a wider range of populations, potentially leading to complex deficiency alleles.
The patient was also heteroallelic for a previously described deletion of the promoter region and exon 1, resulting from recombination between flanking Alu repetitive sequences. This mutation is not detected in heterozygosity by current standard methods of genomic DNA PCR or of cDNA PCR, but should be suspected when the mutation on one allele is not easily identified. We have now found that this mutation is relatively common, accounting for four alleles in 29 unrelated patients we have studied. All four of these patients carried the originally reported 26 nt recombination joint rather than the 16 nt recombination joint reported in one patient (8) . This could be due to a more ancient derivation of the 26 nt mutation, or greater stability of the 26 versus the 16 nt joints.
MATERIALS AND METHODS
Determination of ADA activity and metabolite concentrations
ADA activity, deoxyATP and deoxyadenosine concentrations were determined essentially as previously described (26) . ADA was determined in the patient's samples by measuring conversion of radiolabeled adenosine to inosine and hypoxanthine in the presence and absence of the specific inhibitor EHNA (27) . RBC ADA of parents and normal was determined using a previously described spectrophotometric assay (27) .
Identification of mutations
Exons 1, 2, 3, 4-5, 6, 7-9 and 10-11 were amplified from genomic DNA as previously described (19, 28, 29) (Table 5 ) and sequenced using cycle sequencing with a fMole kit (Promega) or a thermo sequenase radiolabeled terminator cycle sequencing kit (Amersham). A deletion of the promoter and exon 1 was identified by PCR of genomic DNA using primers flanking the Alu repeats involved in generation of the deletion: sense, -1641 to -1611 nt (BG4850), 5′-GATGAAATGAAATGAAGCTACCATCCACC-CC-3′ and antisense, 2090 to 2060 nt (BG4849), 5′-CTTGATGG-GCTGTTACAGAAGAACTGCAAGG-3′ (numbering as in ref. 30 ). 
Introduction of mutations into the normal ADA cDNA
Mutations were introduced into the normal ADA cDNA in the expression vector pSV2 (pSV2ADANL) by primer directed mutagenesis as described by Ho et al. (31) , as we have previously described (32) . In brief, using PSV2ADANL as template, PCR amplification was used in a two step procedure to generate a fragment that contained the newly introduced mutation surrounded by two unique endogenous restriction sites. Following digestion and purification, the fragment containing the mutation was exchanged by ligation for the homologous fragment in pSV2ADANL. Specifically, two flanking primers, 5′ to a unique SfiI site in the pSV2 vector (nt 57) and 3′ to a unique PpumI site in the ADA cDNA, and sense and antisense mutant primers specific for a Y97C or a L106V mutation were used for amplifications. For generation of cDNA containing both mutations, we first introduced the Y97C mutation which was then used as template for introduction of the L106V mutation. All cDNAs were released from pSV2 by HindIII digestion and cloned with the correct orientation in the HindIII site of pcDNA3 (Invitrogen). All clones were analyzed for sequence using cycle sequencing with either a fMole kit (Promega) or a thermo sequenase radiolabeled terminator cycle sequencing kit (Amersham) to confirm presence of the mutations and absence of PCR errors.
Transfection into Cos cells and transient expression of ADA by normal and mutant clones
Plasmids were amplified and DNA purified using a Qiagen Plasmid Maxi Kit. A 100 mm plate of Cos cells was co-transfected with 20 µg of an ADA construct and 1 µg of pRSVΖ (β-galactosidase gene driven by an RSV promoter) by calcium phosphate-DNA co-precipitation essentially by standard methods with minor modifications as previously described (32) . Medium was changed at 8 h, cells were harvested by scraping at 48 h, washed pellets resuspended in 50 µl 0.001 M Na-phosphate buffer (pH 7.0), and lysed by five cycles of freezing and thawing using dry ice/ethanol and a 37_C water bath and sonication for 10 s at 50 W. The supernatant was collected after centrifugation for 15 min at 4_C in an Eppendorf microfuge.
Determination of β-galactosidase activity and in situ detection of ADA activity β-Galactosidase activity was determined in the lysates of transfected cells as previously described (32) . Lysates containing known amounts of β-galactosidase activity (to control for efficiency of transfection) were electrophoresed in starch gels to separate human from endogenous Cos ADA. Gels were stained to detect ADA activity as previously described (32) , using incubation at 37_C for 1-2 h.
In vitro transcription-translation
Coupled transcription and translation was performed using a TNT Coupled Reticulocyte Lysate kit (Promega) either with incorporation of [ 35 S]methionine (NEN Dupont; >1000 Ci/mmol) or unlabeled. Labeled protein was analyzed on discontinuous SDSpolyacrylamide 10% gels with autoradiography. Unlabeled protein was analyzed for ADA activity on starch gels as described (32) .
Case history
ADA -imunodeficiency was diagnosed in the proband at age 7 months, following pneumocystis pneumonia. As previously reported in detail (33, pt#115), prior to haploidentical transplant with paternal marrow at age 27 months, he was markedly lymphopenic with reduced CD4+ and CD8+ cells. He showed minimal responses to mitogens and alloantigens and no response to candida, streptokinase/streptodornase or poliomyelitis antigens.
Immunoglobulins were within normal ranges (IgG = 414, IgA = 45 and IgM = 20 mg/dl versus age matched normal of 762 ± 209, 50 ± 24 and 58 ± 23, respectively), but no specific antibodies were found to tetanus, diphtheria toxoid or E.coli. He died 9 days after the start of chemoablation, due to cyclophosphamide induced myocardopathy. The patient studied here is a sib of the deceased proband and was diagnosed prenatally as ADA deficient. In accord with the parents' wishes, the pregnancy was carried to term and immunodeficiency as well as enzyme deficiency confirmed postnatally. She was markedly lymphopenic with markedly reduced CD4+ T cells (2%). Her lymphocytes were unresponsive to stimulation in vitro by mitogens, alloantigens and antigens. The patient received a haploidentical transplant at 8 weeks of age following preparation at the same dosages as her brother (33) . Four months after transplant she had vigorous in vitro proliferative responses to mitogens and alloantigens and 1 year after transplant, vigorous antigen responses. All immunoglobulin values were low for the first 2 years after transplant, with IgA not detected for the first 6 months, although specific antibody responses to tetanus, diptheria toxoids and E.coli were detected in normal titers. By 3 years after the transplant, the immunoglobulin levels were within the normal ranges. Her tests of immunity have remained normal and she has lived a normal life now over 9 years since transplant without undue susceptibility to infection and without gamma globulin therapy or antibiotic prophylaxis.
